← FDA DRUG APPROVALS

FDA ANDA · ANDA211368

PANTOPRAZOLE SODIUM

Sponsor: INGENUS PHARMS LLC

APPLICATION
ANDA211368
TYPE
ANDA
ORIGINAL APPROVAL
2019-03-01
LATEST ACTION
2023-09-27
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

PANTOPRAZOLE SODIUMDiscontinued
PANTOPRAZOLE SODIUM EQ 40MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2023-09-27Labeling · Supplement 6 · standardAP
2022-06-09Labeling · Supplement 4 · standardAP
2022-06-09Labeling · Supplement 3 · standardAP
2019-12-20Labeling · Supplement 2 · standardAP
2019-03-01UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →